RARA CRAFT DATABASE for FDA Medical Devices
510(k)K191294

FDA DEVICE FACTS

Transvaginal Access Platform

Applied Medical Resources Corp.

FDA-sourced product information for medical-device development research. Use the official FDA sources at the end of this page when the original public document wording is needed.医療機器開発の調査用に、FDA の公開情報から取った製品情報を示しています。公開文書の原文が必要なときは、このページの最後にある FDA の公式な出典をご覧ください。

DECISION DATESeptember 6, 2019PRODUCT CODEHEW

Indications for use

The Transvaginal Access Platform is intended to be inserted transvaginally to establish a path of entry for minimally invasive instruments while maintaining insufflation during laparoscopic -assisted and vaginal gynecological procedures. The device is also a conduit for the extraction of specimens. Comparison with the Predicate Device

The subject and predicate device have different indications for use statements. The predicate device is indicated only for laparoscopic hysterectomy, while the subject device is indicated for laparoscopic assisted and vaginal gynecologic procedures. The key difference is that the subject device can be used during a procedure that only relies on vaginal access (i.e., no laparoscopic access), as well as laparoscopic-assisted gynecologic procedures other than hysterectomy. In addition, the subject device indication uses the term “maintaining insufflation” versus the “maintaining pneumoperitoneum” term used in the predicate device indication. This change in terminology is to account for insufflation of the vaginal canal when the subject device is in use.

The subject and predicate device have the same intended use – establishing a path of entry for instruments, maintaining insufflation, and serving as a conduit for extraction of specimens during minimally invasive gynecologic procedures.

The subject and predicate device have different technological characteristics, including device retention, instrument compatibility, specimen removal method and size, device removal, and device materials. These differences in technological characteristics do not raise different questions of safety or effectiveness.

Discussion of Performance Data

The following performance testing was provided to support a substantial equivalence determination:

• Sterilization validation

• Shelf life testing in cluding transportation simulation, package integrity, and device functionality testing

• Biocompatibility including cytotoxicity per ISO 10993- 5 and irritation and sensitization testing per ISO 10993-10

• Mechanical performance testing including assessments of the following: o Maintenance of transvaginal access o Facilitation of instrument access to surgical site o Device removal o Device retention o Maintenance of insufflation

• Clinical performance data o Baekelandt et al (2018) – randomized, single-center, single-blinded trial to compare hysterectomy by Transvaginal Natural Orifice Transluminal Endoscopic Surgery (vNOTES) versus total laparoscopic hysterectomy (TLH) (n=70) o International Natural Orifice Transluminal Endoscopic Surgery (iNOTESs) Society Registry data (n=906) o Both data sets demonstrated acceptable rates of peri - and post -operative complications following use of the subject device.

See the full product information製品情報をすべて見るには

Device description, AI/software, PCCP, evaluation and limitations are available with an account: seven days of full access after free registration, then with the paid plan.機器の説明、AI・ソフトウェア、PCCP、評価、制限事項は、アカウントでご覧いただけます。無料登録から 7 日間はすべて利用でき、その後は有料プランでご利用いただけます。

Start free 7-day access7日間無料で利用するLog inログイン

OFFICIAL FDA SOURCES

FDA Record and Public Document Status

Record and document link states are stored separately.FDA Record と公開文書のリンクの状態は、別々に記録しています。

Information reviewed:情報の確認日: August 25, 2026